Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. - Suppr | 超能文献

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

作者信息

Jones R N, Pfaller M A, Stilwell M

机构信息

University of Iowa College of Medicine, Iowa City, Iowa, USA. ronald-jones@ jonesgr.com

出版信息

Diagn Microbiol Infect Dis. 2001 Feb;39(2):133-5. doi: 10.1016/s0732-8893(00)00233-9.

DOI:10.1016/s0732-8893(00)00233-9

Abstract

BMS 284756, a novel des-fluoroquinolone with an expanded potency versus Gram-positive pathogens, demonstrated potent activity against a wide range of 3,541 ciprofloxacin-resistant (MIC, > or = 2 microg/ml) Gram-positive cocci. These strains were selected from more than 24,000 isolates gathered as part of the 1999 SENTRY Antimicrobial Surveillance Program. Further clinical development appears warranted.

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

Diagn Microbiol Infect Dis. 2001 Feb;39(2):133-5. doi: 10.1016/s0732-8893(00)00233-9.

2

Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.加替沙星对从北美和南美患者感染中分离出的1676株耐环丙沙星革兰氏阳性球菌的抗菌活性。

Diagn Microbiol Infect Dis. 1998 Nov;32(3):247-52. doi: 10.1016/s0732-8893(98)00101-1.

3

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).

J Antimicrob Chemother. 2002 May;49(5):851-5. doi: 10.1093/jac/dkf028.

4

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.莫西沙星对环丙沙星敏感性降低的病原体的活性。

J Antimicrob Chemother. 1999 Nov;44(5):621-7. doi: 10.1093/jac/44.5.621.

5

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).环丙沙星或左氧氟沙星的抗菌药敏试验结果能否预测对新型氟喹诺酮类药物加替沙星的敏感性？：来自哨兵抗菌监测计划（1997 - 1999年）的报告

Diagn Microbiol Infect Dis. 2001 Apr;39(4):237-43. doi: 10.1016/s0732-8893(01)00229-2.

6

In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.司帕沙星、环丙沙星、氧氟沙星及其他抗生素对革兰氏阳性球菌血流感染分离株的体外活性

Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.

7

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.采用三种方法检测BMS 284756（T-3811）对淋病奈瑟菌的抗菌活性。

Int J Antimicrob Agents. 2001 Nov;18(5):437-40. doi: 10.1016/s0924-8579(01)00438-1.

8

In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.近期革兰氏阳性分离株对环丙沙星、左氧氟沙星和曲伐沙星的体外敏感性

Diagn Microbiol Infect Dis. 1998 Oct;32(2):115-8. doi: 10.1016/s0732-8893(98)00078-9.

9

Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.新型氟喹诺酮类药物DU-6859a对革兰氏阳性球菌的体外活性比较

Antimicrob Agents Chemother. 1994 Mar;38(3):611-5. doi: 10.1128/AAC.38.3.611.

10

In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.

Chemotherapy. 1992;38(2):99-106. doi: 10.1159/000238948.

引用本文的文献

1

Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.加雷沙星在体外及小鼠肺炎模型中对喹诺酮耐药肺炎链球菌菌株的活性。

Antimicrob Agents Chemother. 2004 Mar;48(3):765-73. doi: 10.1128/AAC.48.3.765-773.2004.

2

Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.加替沙星治疗金黄色葡萄球菌或草绿色链球菌所致实验性心内膜炎的疗效。

Antimicrob Agents Chemother. 2004 Jan;48(1):86-92. doi: 10.1128/AAC.48.1.86-92.2004.

3

Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.口服加替沙星在健康受试者中的多剂量安全性和药代动力学

Antimicrob Agents Chemother. 2003 Jul;47(7):2256-63. doi: 10.1128/AAC.47.7.2256-2263.2003.

4

Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.加雷沙星（BMS-284756）对环丙沙星敏感或耐药金黄色葡萄球菌的突变预防浓度。

Antimicrob Agents Chemother. 2003 Mar;47(3):1023-7. doi: 10.1128/AAC.47.3.1023-1027.2003.

5

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.DNA回旋酶和拓扑异构酶IV的双重靶向作用：新型去氟喹诺酮类药物加替沙星（BMS-284756，T-3811ME）的靶点相互作用

Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.

6

Gatifloxacin: a review of its use in the management of bacterial infections.加替沙星：其在细菌感染治疗中的应用综述

Drugs. 2002;62(1):169-207. doi: 10.2165/00003495-200262010-00007.

7

Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.BMS-284756与氟喹诺酮类和β-内酰胺类药物对革兰氏阳性临床分离株的抗菌活性比较。

Antimicrob Agents Chemother. 2002 Jan;46(1):234-8. doi: 10.1128/AAC.46.1.234-238.2002.